Departments of *Internal Medicine, and †Radiology, University of Michigan, Ann Arbor, Michigan; ‡Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan; and §VA Ann Arbor Health Services Research and Development Center for Clinical Research, Ann Arbor, Michigan.
Inflamm Bowel Dis. 2017 Oct;23(10):1803-1809. doi: 10.1097/MIB.0000000000001181.
Endoscopic balloon dilation (EBD) is an effective method for treating stricture-related obstruction in Crohn's disease. We aimed to identify factors predictive of successful avoidance of surgery, including endoscopic features, in patients undergoing balloon dilation.
We performed a retrospective review of patients with symptomatic Crohn's disease-related intestinal strictures undergoing EBD. Clinical, medication use, laboratory, and dilation data, including the minimum and maximum balloon sizes used, and number of balloons used per endoscopic session were collected. Multivariate analysis by Cox proportional hazard regression was used to model future surgical bowel resection.
In a total of 135 subjects undergoing 292 dilations, multivariate modeling demonstrated that failure to achieve a maximum dilation of 14 mm or more increased the risk of surgery (hazard ratio [HR] 2.88, 95% confidence limit [CL], 1.10-7.53). Although there was no difference in the risk of future surgery between maximum EBD sizes of 14 to 15 mm and 16 to 18 mm, those reaching 16 to 18 mm exhibited a longer interval between subsequent dilations (mean 240 ± 136.7 versus 456 ± 357.3 d, respectively, P = 0.023). Endoscope passage at index dilation was not predictive of future surgery (HR 0.63, 95% CL, 0.31-1.26). Adjusting for covariates of EBD size, stricture location and type, a C-reactive protein >1.5 mg/dL (HR 2.60, 95% CL, 1.12-5.94), and anti-tumor necrosis factor initiation after index EBD (HR 2.39, 95% CL, 1.09-5.25) increased the risk of future surgery.
Although dilation calibers larger than 14 to 15 mm were not more protective against future surgery, those reaching 16 to 18 mm underwent maintenance dilation less frequently. The risk of surgery associated with post-EBD anti-tumor necrosis factor initiation suggests that effective therapy is often used too late in the disease course.
内镜球囊扩张(EBD)是治疗克罗恩病相关狭窄性梗阻的有效方法。我们旨在确定预测避免手术成功的因素,包括接受球囊扩张的患者的内镜特征。
我们对接受 EBD 治疗有症状的克罗恩病相关肠道狭窄的患者进行了回顾性研究。收集了临床、药物使用、实验室和扩张数据,包括使用的最小和最大球囊尺寸,以及每次内镜检查使用的球囊数量。使用 Cox 比例风险回归的多变量分析来建立未来手术肠切除的模型。
在总共 135 名接受 292 次扩张的患者中,多变量建模表明,未能达到 14mm 或更大的最大扩张增加了手术风险(风险比[HR]2.88,95%置信区间[CL]1.10-7.53)。尽管最大 EBD 尺寸为 14 至 15mm 和 16 至 18mm 之间的手术风险无差异,但达到 16 至 18mm 的患者的后续扩张间隔更长(分别为 240±136.7 天和 456±357.3 天,P=0.023)。在索引扩张时通过内镜并不预测未来的手术(HR 0.63,95%CL,0.31-1.26)。调整 EBD 大小、狭窄位置和类型、C 反应蛋白>1.5mg/dL(HR 2.60,95%CL,1.12-5.94)和索引 EBD 后起始抗肿瘤坏死因子(HR 2.39,95%CL,1.09-5.25)的协变量后,手术风险增加。
尽管扩张口径大于 14 至 15mm 并不能更好地预防未来的手术,但达到 16 至 18mm 的患者进行维持扩张的频率较低。与 EBD 后起始抗肿瘤坏死因子相关的手术风险表明,有效的治疗通常在疾病过程中太晚使用。